ARCT OTC deficiency and CF programs near regulatory and phase milestones
ARCT says upcoming phase II data and regulatory updates for its OTC deficiency program will clarify pediatric and adult path forward. CF program runs a 12-week open-label study; phase III decision and major funding tied to Q4.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.